KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Regeneron Pharmaceuticals (REGN) EBITDA Margin: 2009-2025

Historic EBITDA Margin for Regeneron Pharmaceuticals (REGN) over the last 17 years, with Sep 2025 value amounting to 39.33%.

  • Regeneron Pharmaceuticals' EBITDA Margin fell 20.00% to 39.33% in Q3 2025 from the same period last year, while for Sep 2025 it was 32.19%, marking a year-over-year decrease of 313.00%. This contributed to the annual value of 31.58% for FY2024, which is 24.00% up from last year.
  • As of Q3 2025, Regeneron Pharmaceuticals' EBITDA Margin stood at 39.33%, which was up 2.16% from 38.50% recorded in Q2 2025.
  • In the past 5 years, Regeneron Pharmaceuticals' EBITDA Margin ranged from a high of 1,659.20% in Q1 2022 and a low of 22.42% during Q4 2024.
  • Its 3-year average for EBITDA Margin is 32.39%, with a median of 30.59% in 2023.
  • As far as peak fluctuations go, Regeneron Pharmaceuticals' EBITDA Margin skyrocketed by 161,562bps in 2022, and later plummeted by 163,153bps in 2023.
  • Regeneron Pharmaceuticals' EBITDA Margin (Quarterly) stood at 44.29% in 2021, then spiked by 118,911bps to 1,233.40% in 2022, then plummeted by 119,684bps to 36.56% in 2023, then plummeted by 1,414bps to 22.42% in 2024, then dropped by 20bps to 39.33% in 2025.
  • Its last three reported values are 39.33% in Q3 2025, 38.50% for Q2 2025, and 27.92% during Q1 2025.